Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
01:20pm, Wednesday, 13'th May 2026
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
08:00am, Wednesday, 13'th May 2026
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Interme
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Monday, 11'th May 2026
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
03:59pm, Thursday, 07'th May 2026
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J
UroGen Pharma to Present at Upcoming Investor Conferences
08:00am, Thursday, 07'th May 2026
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
06:01pm, Wednesday, 06'th May 2026
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
10:30am, Wednesday, 06'th May 2026
Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
08:00am, Wednesday, 06'th May 2026
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achi
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
08:00am, Wednesday, 29'th Apr 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
08:00am, Monday, 30'th Mar 2026
72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pha
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 06'th Mar 2026
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
01:53am, Thursday, 05'th Mar 2026
UroGen Pharma faces a pivotal period as ZUSDURI, its recently approved bladder cancer therapy, is positioned for accelerated adoption following a permanent J-Code in 2026. ZUSDURI's peak sales are ant
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
12:57pm, Monday, 02'nd Mar 2026
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
10:10am, Monday, 02'nd Mar 2026
Urogen Pharma (URGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.8 per share a year ago.
